CNC
REGN icon

Canandaigua National Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Canandaigua National Corp’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,779
Closed -$1.34M – 271
2020
Q4 		$1.34M Sell
2,779
-12
-0.4% -$6.48K 0.24% 110
2020
Q3 		$1.56M Sell
2,791
-107
-4% -$64.9K 0.28% 97
2020
Q2 		$1.81M Buy
+2,898
New +$1.64M 0.33% 85

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Canandaigua National Corp's REGN Position: Q1 2021 in Review

Canandaigua National Corp sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 2,779 shares — an estimated $1.34M sold.

Canandaigua National Corp first reported a position in REGN in Q2 2020 and held it in 3 quarters. The position peaked at $1.81M in Q2 2020. 925 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

  • Canandaigua National Corp reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Canandaigua National Corp sold 2,779 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $1.34M.
  • Canandaigua National Corp first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Canandaigua National Corp's Regeneron Pharmaceuticals position peaked at $1.81M in Q2 2020.
  • 925 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Canandaigua National Corp's 13F filing for Q1 2021, filed 5 Apr 2021.